Gadolinium-enhanced aneurysm wall imaging of unruptured intracranial aneurysms

Gadolinium-enhanced aneurysm wall imaging of unruptured intracranial aneurysms - LUMINA-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41834

Enrollment

Registered

2014-08-06

Start date

2014-10-14

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unruptured intracranial aneurysm - protuberance of a blood vessel

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18 years or older. Patient is diagnosed with one or more unruptured intracranial aneurysms confirmed on digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA). Informed consent signed by subject.

Exclusion criteria

Exclusion criteria: Medical history of sever renal insufficiency: GFR

Design outcomes

Primary

Measure	Time frame
The presence (present/absent) of gadolinium-enhancement of the aneurysm wall on 3 Tesla MR-angiography (MRA). If evaluation of the first 15 patients results in the possibility of a semi-quantitative outcome endpoint for contrast enhancement (none/mild/severe/complete), we will discuss the use of this endpoint with the entire study group.	—

Secondary

Measure	Time frame
Determinants of gadolinium-enhancement: a. The use of anti-inflammatory drugs (including acetylsalicylic acid); b. Hypertension; c. The size of the aneurysm; d. The relation with smoking.	—

Countries

Netherlands

Outcome results